Breast cancer is a common malignancy among women and is associated with poor 5-year survival rates. Gene radiotherapy, that is, gene therapy combined with radiotherapy, has been extensively studied as a new mode of therapy, but most studies have assessed only one gene. Here, we inserted two anti-oncogenes, ING4 (inhibitor of growth family member 4) and interleukin-24 (IL-24), in the same bicistronic adenovirus vector and explored the effect of dual-gene therapy combined with radiotherapy on breast cancer cells. Flow cytometry assays showed that adenovirus-mediated ING4 and IL-24 expression could suppress growth, promote apoptosis and induce G2/M cell-cycle arrest in MDA-MB-231 cells. Moreover, animal model studies demonstrated that the combination of ING4/IL-24 gene therapy and radiotherapy significantly suppressed cell proliferation and inhibited tumor growth (Po0.05). Mechanistically, the pro-apoptotic response likely involved the upregulation of Bax and Caspase-3 and the downregulation of Bcl-2. Thus, this study indicates that the co-expression of the two anti-oncogenes, ING4 and IL-24, could significantly promote radiotherapy sensitivity in MDA-MB-231 breast cancer cells.
INTRODUCTION
Breast cancer is a common malignancy among women and is the second leading cause of cancer-related mortality, after lung cancer. 1 The incidence of breast cancer has drastically increased over the past several decades. Treatment options for breast cancer include surgery, radiation and therapeutic drugs. Unfortunately, current treatments have not improved the poor 5-year survival rates of patients with breast cancer, primarily due to metastasis and resistance to chemotherapy and radiation.
It was reported that post-operative radiotherapy could decrease local recurrence and prolong survival. 2, 3 However, post-operative radiotherapy could also promote non-cancer-related death, especially in cases of radioactive heart injury. 4, 5 Such side effects limit the clinical application of normal doses of radiotherapy.
Gene therapy was evaluated as one of the top 10 scientific discoveries in 2009 by the journal Science and will surely be recognized as a major scientific achievement. 6, 7 Cancer gene therapy represents a new and promising therapeutic modality for cancer treatment. In addition, various strategies have been developed for combining gene therapy or molecular therapy with radiotherapy to maximize the selective pressure against cancer cell growth, while minimizing treatment-associated toxicity. 8 Cancer is characterized as a multistep process of genetic and molecular changes in oncogenes and antioncogenes. Because of this complex process, the efficacy of a single gene-mediated cancer therapy may be limited by the challenge of identifying a pivotal gene that regulates cancer occurrence and progression. Therefore, multigene-based combination therapy may be a more effective breast cancer gene therapy strategy. To our knowledge, however, a comparison of radiotherapy combined with gene therapy of two or more antioncogenes and single gene radiotherapy has not been reported for breast cancer.
As a member of the inhibitor of growth (ING) family of proteins, ING4 can significantly suppress tumor growth via cell-cycle arrest, apoptosis and inhibition of tumor angiogenesis. [9] [10] [11] [12] [13] [14] We previously demonstrated that adenovirus-mediated ING4 expression could remarkably inhibit the growth of MDA-MB-231 breast cancer cells in vitro and in vivo. 15 Another tumor suppressor, interleukin-24 (IL-24), is a unique cytokine that belongs to the IL-10 family and was originally identified by subtraction hybridization in human melanoma cells treated with interferon-b and mezerein. 16, 17 Extensive studies have shown that IL-24 displays ubiquitous anti-tumor properties and tumor-specific killing activity in a broad spectrum of cancer cells. 18 Thus, ING4 and IL-24 are promising tumor suppressors that negatively modulate tumor growth via multiple pathways.
In this study, MDA-MB-231 human breast cancer cells were treated in vitro with ING4 and IL-24 gene therapy, radiotherapy or a combination of therapies. Then, growth inhibition, apoptosis and cell-cycle arrest were assessed for each treatment group. In addition, the expression of the apoptosis-related genes Bax, Bcl-2 and Caspase-3 were detected. Finally, the growth inhibitory effects of radiotherapy and the combined ING4 and IL-24 gene therapy were determined using a xenograft animal model of breast cancer. Our results demonstrate that adenovirus-mediated ING4-IL-24 expression (Ad-ING4-IL-24) can notably inhibit the growth of MDA-MB-231 human breast cancer cells. Furthermore, the co-expression of these two tumor suppressors can significantly enhance the radiotherapy sensitivity of MDA-MB-231 cancer cells.
MATERIALS AND METHODS

Vectors, cell lines, reagents and mice
The Ad-ING4-IL-24 and Ad-replication-incompetent adenoviral vectors were constructed and maintained by our laboratory. 19, 20 The MDA-MB-231 human breast cancer cell line was purchased from the American Type Culture Collection (Shanghai, China) and cultured in RPMI 1640 (Gibco, Shanghai, China) supplemented with 10% fetal bovine serum (Hyclone, Shanghai, China). The real-time PCR (RT-PCR) detection kit was purchased from Invitrogen (Shanghai, China). The methyl thiazolyl tetrazolium (MTT) kit was purchased from Sigma (Shanghai, China). The Annexin V-PE/7-AAD (Annexin V-phycoerythrin/7-amino-actinomycin D) apoptosis detection kit was purchased from BD Biosciences (Shanghai, China). The in situ cell death detection kit was purchased from Roche Applied Science (Shanghai, China). Antibodies specific for Bax, Bcl-2 and Caspase-3 were purchased from Cell Signaling (Shanghai, China); antibodies specific for ING4 and IL-24 were purchased from Abcam (Cambridge, UK). The UltraSensitive SP kit was purchased from Maixin (Fuzhou, China). Athymic nude mice were purchased from the Shanghai Experimental Animal Center (Shanghai, China) and maintained in the animal facility at Soochow University according to the guidelines defined by the Soochow University animal research committee. The Soochow University Review Board and Ethics Committee approved the animal studies.
Control and experimental groups
MDA-MB-231 human breast cancer cells were divided into the following five treatment groups: (1) cells treated with phosphate-buffered saline (PBS), (2) cells infected with Ad-ING4-IL-24 (Ad-ING4-IL-24 group), (3) cells infected with a blank adenovirus (Ad-GFP (adenovirus-treated green fluorescent protein) group, used as negative control), (4) cells treated with radiotherapy by exposure to 6 Gray (Gy) g-ray (6 Gy group) and (5) cells treated with a combination of radiotherapy and gene therapy by infection with Ad-ING4-IL-24 and exposure to 6 Gy g-ray (combination group). All viral infections were performed at the optimal multiplicity of infection of 100 as previously described. 11, 15, 20 The combination group was first infected with Ad-ING4-IL-24 at 100 multiplicity of infection for 48 h and exposed to 6 Gy g-ray, followed by continuous culture.
MTT assays
MDA-MB-231 human breast cancer cells in all the treatment groups were cultured in 96-well culture plates for the indicated time periods (0-4 days). Before treatment and at different time points after treatment, the optical density at 570 nm (OD 570 ) was recorded, and the viability of MDA-MB-231 tumor cells was analyzed using the MTT kit, according to the manufacturer's protocol. Inhibition ratios were calculated using the following formula: Inhibition ratio ¼ (OD 570 of the control group À OD 570 of the experimental group)/OD 570 of the control group.
Apoptosis and cell-cycle detection by flow cytometry MDA-MB-231 human breast cancer cells in all the treatment groups were harvested after treatment for 48 h and washed in cold PBS; the apoptosis ratio was assessed by flow cytometry using the Annexin V-PE/7-AAD apoptosis detection kit, according to the manufacturer's protocol. Briefly, MDA-MB-231 cells (1 Â 10 6 ) were incubated with 5 ml Annexin V-PE and 5 ml 7-AAD in 100 ml of 1 Â Annexin V-binding buffer at room temperature. After incubating for 15 min, 400 ml of 1 Â binding buffer was added, and the apoptotic cells were then analyzed by flow cytometry. In addition, a portion of cells from each group was fixed with cold 70% ethanol for 12 h, and the cells from each group were stained with propidium iodide for cellcycle analysis by flow cytometry. All experiments were repeated three times.
RT-PCR analysis
The transcription of the apoptosis-related genes Bax, Bcl-2 and Caspase-3, as well as ING4 and IL-24, were detected by RT-PCR analysis. Briefly, MDA-MB-231 cells (5 Â 10 6 ) in all the groups were cultured for 48 h and collected, and the total cellular RNA was extracted with Trizol. The firststrand cDNA was reverse transcribed using 2 mg RNA template, Oligo d(T)18 (0.5 mg) primers and MuMLV reverse transcriptase (50 U). The PCR reaction was carried out using the following primers: Immunofluorescent staining MDA-MB-231 human breast cancer cells in all the groups were plated onto glass cover slips in a 24-well plate and given the corresponding treatments. Forty-eight hours later, cover slips were removed, fixed with 4% paraformaldehyde and immunostained with antibodies against ING4 or IL-24. Laser scanning confocal microscopy (Carl Zeiss, Munich, Germany) was used to examine co-staining of the above molecules and GFP.
Western blot analysis MDA-MB-231 human breast cancer cells from each group were collected, washed with cold PBS and lysed. Total cellular lysates (100 mg per lane) were then resolved by 12% sulfate-polyacrylamide gel electrophoresis and subsequently transferred onto polyvinylidene difluoride membranes. The membranes were blocked with 5% (w/v) non-fat dry milk in Tris-buffered saline containing 0.05% Tween-20, incubated with primary antibodies specific for Bax, Bcl-2, Caspase-3 and GAPDH (an internal control) in the blocking solution for 1 h and incubated with peroxidase (horseradish peroxidase)-conjugated secondary antibody for 1 h. Subsequently, the membranes were washed and developed using the super-enhanced chemiluminescence detection kit (Jianglaibio, Shanghai, China), according to the manufacturer's protocol. The protein bands were visualized after exposing the membranes to X-ray film.
Animal studies
Athymic nude mice (five in each group) were subcutaneously inoculated with 2 Â 10 6 MDA-MB-231 human breast cancer cells into the second thoracic mammary fat pad and monitored daily for tumor growth. Tumor volume was measured with a caliper and calculated using the following formula: tumor size ¼ ab 2 /2, where a is the larger and b is the smaller of the two dimensions. Day 0 was defined as the point when the tumors reached a mean tumor volume of approximately 0.1 cm 3 . At day 0, tumorbearing mice were randomly divided into five groups and treated according to the previously described experimental and control groups.
Mice in the Ad-GFP group or the Ad-ING4-IL-24 and combination treatment groups received one intratumoral injection of 1 Â 10 8 plaque forming units (pfu) of blank adenovirus or Ad-ING4-IL-24 (1 Â 10 8 pfu), respectively, every other day for a total of five injections. For the radiotherapy group, tumor-bearing mice were anaesthetized on day 0 by peritoneal injection of 10% chloral hydrate and fixed onto an anatomy plate. Tumor masses were then exposed to 6 Gy irradiation a single time by 5 MeV g-ray with the tumor-source distance of 100 cm and the dose rate of 2 Gy/min. During irradiation, mice were protected by a 3-mm-thick lead grid to avoid radioactive damage to other body parts. In the combination group, tumor-bearing mice were first treated with two injections of Ad-ING4-IL-24, and then mice were exposed to irradiation similar to the radiotherapy group 24 h after the second intratumoral injection.
Tumor volume, weight and inhibition rate
The maximum diameter (a) and vertical diameter (b) of all tumors were measured at the time of treatment and every 2 days following therapy. The tumor volumes were calculated with the formula: V (mm 3 ) ¼ ab 2 /2, where a is the larger and b is the smaller of the two dimensions. Twelve days after the initial treatments, the mice were killed, and all tumors were removed and weighed. The tumor inhibition rate was calculated using the formula: Inhibition rate (%) ¼ (1 À the average tumor weight in an experimental group/the mean tumor weight in the control group) Â 100%.
Immunohistochemistry analysis
The expression levels of Bax, Bcl-2, Caspase-3, ING4 and IL-24 in MDA-MB-231 human breast cancer cells xenografts were analyzed by immunohistochemistry using the UltraSensitive SP kit, according to the manufacturer's protocol. The presence of buffy or brown diaminobenzidine precipitates is indicative of positive reactivity. The integral optical density (IOD) of immunohistochemical intensity was then calculated using the Image-Pro Plus 6.0 software (Media Cybernetics, Rockville, MD, USA). Each value represents the integral optical density or microvessel density counted at a high-power view ( Â 400) by microscopy. The mean value represents the average number derived from the analysis of five highpower fields for each case.
Statistical analysis
All data are presented as the mean ± s.d. Significant differences between two samples were evaluated by t-tests using SPSS 10.0 software (IBM, Armonk, NY, USA). A value of Po0.05 was considered statistically significant. Enhanced tumor suppression The cell viability of each group was examined daily in vitro before and after treatment using MTT assays. As shown in Figure 2 , irradiation could slightly suppress MDA-MB-231 human breast cancer cell growth in a time-dependent manner compared with the Ad-GFP and PBS control groups. Interestingly, combined treatment with Ad-ING4-IL-24 þ 6 Gy significantly inhibited the growth of MDA-MB-231 tumor cells to a greater extent than the Ad-ING4-IL-24 or 6 Gy g-ray groups (Po0.05).
Enhanced apoptosis and cell-cycle arrest Annexin V-PE and 7-AAD double-positive staining by flow cytometry showed that Ad-ING4-IL-24 treatments, irradiation and combination therapy could induce MDA-MB-231 tumor cell apoptosis (Figure 3a) when compared with the Ad-GFP and PBS groups. Moreover, the apoptosis rate of the combination group was significantly higher than the Ad-ING4-IL-24 and 6 Gy groups alone, indicating that Ad-ING4-IL-24 treatment could enhance the sensitivity of MDA-MB-231 tumor cells to g-ray radiation (Figure 3c ). The cell-cycle distribution of MDA-MB-231 human breast carcinoma cells in each treatment group was analyzed by flow cytometry. As shown in Figures 3b and c , the proportion of MDA-MB-231 tumor cells in the G2/M phase after treatment with PBS, Ad-GFP, Ad-ING4-IL-24, 6 Gy or a combination were 11.61 ± 1.26%, 13.52±1.35%, 32.36±3.62%, 47.39±4.24% and 59.26±4.56%, respectively.
Tumor suppression in vivo
The MDA-MB-231 human breast cancer cell xenograft model in nude mice was successfully established (Figure 4a ). Tumor volumes were measured before treatments and every 2 days after treatments (Figure 4b ). Twelve days after the initial therapy, the mice were killed, and tumor masses were removed. Tumor masses were weighed (Figure 4c) , and based on the tumor weight of the PBS group, the final tumor inhibition ratios of the Ad-ING4-IL-24, 6 Gy and combination groups were 67.7%, 29.1% and 88.1%, respectively.
Detection of apoptosis-related genes Transcriptions of the apoptosis-related genes Bax, Bcl-2 and Caspase-3 were analyzed by RT-PCR for each group in vitro. Bax and Caspase-3 transcripts were significantly increased in the Ad-ING4-IL-24, 6 Gy and combination groups; however, the Bcl-2 transcription was significantly decreased in these treatment groups. In addition, the levels of Bax and Caspase-3 mRNA were even higher, and the level of Bcl-2 mRNA was significantly lower in the combination group than in the Ad-ING4-IL-24 and 6 Gy groups (Figures 5a and b) . Western blots for the expression of Bax, Bcl-2 and Caspase-3 protein showed results consistent with the RT-PCR data (Figures 5c and d) .
In the MDA-MB-231 human breast carcinoma xenograft model, immunohistochemistry was used to detect expression of Bax, Bcl-2 and Caspase-3 after treatment with Ad-ING4-IL-24, radiotherapy, combination therapy or Ad-GFP (Figure 5e ). The expression levels of Bax and Caspase-3 in the Ad-ING4-IL-24, 6 Gy and combination groups were significantly increased, whereas Bcl-2 expression level in these treatment groups was significantly decreased. In the combination group, Bax and Caspase-3 expression levels were increased, and Bcl-2 expression level was significantly reduced compared with the Ad-ING4-IL-24 and radiotherapy groups (Figure 5f ).
DISCUSSION
Breast cancer cells generally have an intermediate sensitivity to radiotherapy. Therefore, radiotherapy is often integrated with surgery and chemotherapy to achieve a radical cure for breast cancer. The application of radiation therapy has been limited because of possible injuries to normal tissues caused by large doses. Fortunately, gene therapy combined with radiotherapy, that is, gene radiotherapy, is currently regarded as a new mode of treatment. 21 The advantages of gene radiotherapy include the observation that radiation can increase the efficiency of gene transfer and thus improve the effect of gene therapy. 22 Gene therapy can also enhance radiation therapy by increasing radiosensitivity, reducing radiation injury to normal tissues and changing oxygenation of tumor cells. 23 Consequently, gene radiotherapy has become an exciting innovation in the field of oncotherapy.
Combination radiotherapy based on a single gene has been extensively studied; however, multigene-based combination radiotherapy has rarely been reported. Theoretically, multigenebased combination radiotherapy represents an effective practice in cancer gene therapy that can achieve greater therapeutic benefit by targeting multiple pathways. 24 There are currently two main approaches for multi-gene therapy. First, multipleindependent vectors carrying different genes may be simultaneously transfected or infected into target cells. The advantages of this approach are the convenient proportional adjustment of each expression vector combination and the coordination of time. The disadvantage is that the efficiency of multi-gene co-expression is too low and onerous. 25, 26 A second approach for multi-gene therapy is to achieve the co-expression of multiple genes using one vector. 27 In comparison to the first approach, a multi-gene co-expression vector can increase the efficiency of transfection and expression. Based on the anti-tumor properties of ING4 and IL-24, we speculated that the combination of these two tumor suppressors would exert enhanced tumor suppression. The low efficiency of gene transfer is the bottleneck in gene therapy; therefore, we constructed the ING4-IL-24 bicistronic adenovirus co-transfection vector (Ad-ING4-IL-24). 19, 20 In this study, we not only conducted double-gene therapy with a bicistronic gene expression system using one vector but also combined gene therapy with radiotherapy for breast cancer treatment, which has never been reported for breast or other types of cancer. The MTT results showed that the combination treatment could significantly inhibit the proliferation of MDA-MB-231 cells, and the flow cytometry results proved that the apoptosis ratio in the combination group was much higher than that of either the Ad-ING4-IL-24 or the radiotherapy group alone (Po0.05). This phenomenon indicates that the co-expression of ING4-IL-24 can enhance the tumor-inhibition effect of radiotherapy, and their combination is an effective therapy in a model for breast cancer.
Cellular apoptosis often occurs after cell-cycle arrest, 28 and the anti-cancer mechanism of many treatments is mediated by the induction of cell-cycle-specific apoptosis. In our study, the cellcycle status of MDA-MB-231 cells in each treatment group was analyzed by flow cytometry. The results showed that treatment with Ad-ING4-IL-24 significantly increased the percentage of cells in the G2/M phase. Moreover, the cell-cycle phase determines the relative radiosensitivity of a cell: cells are most radiosensitive in the G2/M phase, less sensitive in the G1 phase and least sensitive during the latter part of the S phase. 29 In our study, Ad-ING4-IL-24 treatment caused more MDA-MB-231 breast cancer cells to arrest in the G2/M stage, which consequently enhances radiotherapy sensitivity.
Tumor cell resistance to radiotherapy is related to the regulation of apoptosis. Caspases are a group of cysteine proteases, and their family members have an important role in the apoptotic process. Currently, 14 members of this family have been identified; however, Caspase-3 is a key enzyme in apoptosis activation and is a major effector of apoptosis. Bcl-2 and Bax constitute a rheostat that sets the threshold of susceptibility to apoptosis. 30 In our study, the transcription and expression of the pro-apoptotic genes Bax and Caspase-3 in the combination group were significantly higher than that of the other groups. The anti-apoptotic gene Bcl-2 was significantly downregulated in the combination group compared with the Ad-ING4-IL-24 and radiotherapy groups. The upregulation of Bax and Caspase-3 and the downregulation of Bcl-2 in MDA-MB-231 human breast cancer cells most likely contributed to the radiotherapy sensitization induced by Ad-ING4-IL-24, which enhanced the apoptosis of tumor cells.
CONCLUSION
The present study indicates that the co-expression of the two tumor suppressors ING4 and IL-24 could significantly promote MDA-MB-231 cancer cell sensitivity towards radiotherapy.
